Vyvanse vs Adderall XR: Switching Between Them Safely

How Vyvanse and Adderall XR Compare Pharmacologically

Both medications deliver amphetamine to the central nervous system, but they get there differently. Vyvanse (lisdexamfetamine dimesylate) is a prodrug: it binds the amino acid L-lysine to d-amphetamine, requiring enzymatic cleavage in red blood cells before the active drug reaches the brain [1]. Adderall XR (mixed amphetamine salts) contains a 3:1 ratio of d-amphetamine to l-amphetamine in an immediate-release and delayed-release bead mixture [2].

This prodrug mechanism gives Vyvanse a smoother pharmacokinetic curve. Peak plasma concentration (Tmax) occurs approximately 3.5 hours after ingestion for Vyvanse versus 2 hours for Adderall XR's first pulse [1][2]. Wigal et al. demonstrated in a laboratory classroom study (N=117) that Vyvanse maintained statistically significant ADHD symptom reduction from 1.5 hours through 13 hours post-dose, with effect sizes (Cohen's d) ranging from 0.89 to 1.35 across time points [3]. The MTA Cooperative Group trial (N=579), which used mixed amphetamine salts as part of its medication algorithm, showed that carefully titrated stimulant therapy produced significantly greater symptom improvement than behavioral treatment alone (effect size 0.56 for combined treatment vs. community care) over 14 months [4].

The l-amphetamine component in Adderall XR adds norepinephrine reuptake inhibition beyond what pure d-amphetamine provides. Some patients report that this makes Adderall XR feel "stronger" at comparable doses, while others find it causes more peripheral stimulation (elevated heart rate, jitteriness) [5]. Neither medication has been shown to be categorically superior to the other in head-to-head randomized trials; the largest systematic reviews consistently classify both as first-line options with similar pooled effect sizes for ADHD symptom reduction [6].

Why Patients Switch Between Vyvanse and Adderall XR

The most frequent reason is insurance coverage. Formulary changes happen annually, and prior authorization requirements shift with them. Before generic lisdexamfetamine became available in August 2023, a 30-day supply of brand Vyvanse averaged $380 to $420 without insurance, while generic Adderall XR cost $30 to $80 [7]. That price gap drove millions of formulary-mandated switches.

Side effects rank second. Vyvanse's smoother onset may produce less appetite suppression during the first two hours compared to Adderall XR, though both medications carry similar rates of decreased appetite (27% to 39%), insomnia (13% to 27%), and dry mouth (4% to 5%) in key trials [1][2]. Some patients tolerate one formulation's side-effect timing better than the other's. A patient who crashes hard at hour 10 on Adderall XR might prefer Vyvanse's longer tail. A patient who feels "flat" for 13 hours on Vyvanse might prefer Adderall XR's slightly shorter window to preserve evening appetite.

Duration of coverage also matters. Clinicians treating college students or professionals with 14-hour workdays sometimes start with Vyvanse specifically because of the 12- to 13-hour coverage window documented by Wigal et al. [3]. Patients with shorter days may find Adderall XR's 10- to 12-hour coverage sufficient and prefer that the medication clears earlier, reducing sleep-onset latency [8].

Dose Conversion: Vyvanse to Adderall XR and Back

No FDA-approved conversion table exists. The most widely cited approximation used in clinical practice maps Vyvanse doses to Adderall XR doses based on d-amphetamine content. Vyvanse 30 mg releases approximately 8.9 mg of d-amphetamine. Adderall XR 10 mg delivers 7.5 mg of d-amphetamine plus 2.5 mg of l-amphetamine [1][2]. The approximate equivalences:

| Vyvanse | Adderall XR (approximate) | |---------|--------------------------| | 20 mg | 5 to 7.5 mg | | 30 mg | 10 mg | | 40 mg | 15 mg | | 50 mg | 20 mg | | 60 mg | 25 to 30 mg | | 70 mg | 30 mg |

These ratios are estimates. Dr. Thomas E. Brown, a clinical psychologist who directed the Brown Clinic for Attention and Related Disorders at Yale, has stated: "Dose equivalence tables for stimulants are starting points, not endpoints. The only reliable measure is each patient's clinical response at each dose" [9]. The American Academy of Pediatrics (AAP) 2019 clinical practice guideline similarly advises that "the clinician should titrate doses to achieve maximum benefit with minimum adverse effects," regardless of which specific stimulant is selected [10].

Patients switching from Vyvanse 70 mg (the ceiling dose) may find that Adderall XR 30 mg feels either too strong or too weak. The l-amphetamine component in Adderall XR makes a milligram-for-milligram comparison imprecise. Start at the calculated equivalent, then adjust in 5 mg increments every 5 to 7 days.

Step-by-Step Switching Protocol

The transition is typically done overnight. There is no pharmacological need to taper off one stimulant before starting the other, because neither Vyvanse nor Adderall XR causes physiological dependence at therapeutic doses in the way benzodiazepines or opioids do [5]. Abrupt discontinuation may cause rebound fatigue and mood dip for one to three days, but these symptoms are self-limited.

A practical protocol looks like this. On the last day of the current medication, take the morning dose as usual. The next morning, take the new medication at the calculated equivalent dose. Schedule a follow-up (telehealth or in-person) at 7 to 14 days to assess symptom control, side effects, and sleep quality. Titrate in 5 to 10 mg increments (for Adderall XR) or 10 mg increments (for Vyvanse) every 5 to 7 days until the patient reaches optimal response [10].

Three clinical checkpoints matter during the first month. First, appetite and weight: weigh the patient at baseline and at the 4-week follow-up. The prescribing information for both medications reports mean weight loss of 1 to 2 kg over the first 4 weeks at therapeutic doses [1][2]. Second, cardiovascular parameters: check resting heart rate and blood pressure at each visit. The FDA label for both drugs warns against use in patients with serious structural cardiac abnormalities [1][2]. Third, sleep: ask specifically about sleep-onset latency. If the new medication is causing insomnia that the previous one did not, the dose may need to be reduced or the timing shifted earlier.

Differences in Abuse Liability

Both Vyvanse and Adderall XR are Schedule II controlled substances under the DEA classification. Vyvanse's prodrug design was engineered specifically to reduce abuse potential via non-oral routes. A 2015 abuse-liability study by Jasinski et al. (N=37) found that intranasal lisdexamfetamine produced significantly lower "drug liking" scores (Emax 61.4 on a 0-100 VAS) compared to equivalent doses of immediate-release d-amphetamine (Emax 82.5, P<0.001) [11]. Oral abuse liability at supratherapeutic doses was similar between the two drugs, meaning Vyvanse's abuse-deterrent properties are route-specific, not absolute.

For patients with a personal or family history of substance use disorder, some clinicians prefer Vyvanse as a risk-reduction strategy. The 2023 AACAP practice parameter for ADHD notes that "long-acting formulations and prodrug stimulants may confer lower diversion risk," though it stops short of mandating them [12]. Adderall XR's bead formulation can be opened and crushed, which has contributed to higher rates of non-prescribed use in college populations (estimated 5% to 35% lifetime prevalence depending on the survey methodology) [13].

What to Expect in the First Two Weeks After Switching

Days one through three often feel different even at equivalent doses. Patients switching from Vyvanse to Adderall XR commonly report a faster, more noticeable onset of effect (sometimes described as a "kick") due to the immediate-release bead component releasing within 30 minutes [2]. Patients moving in the opposite direction, from Adderall XR to Vyvanse, frequently describe a subtler onset that they initially mistake for the medication not working. Both observations are consistent with the pharmacokinetic profiles and do not indicate treatment failure.

By days four through seven, most patients have adjusted to the new onset pattern. The more meaningful clinical question at this point is whether the total duration of coverage matches the patient's daily needs. A 2018 retrospective chart review published in the Journal of Clinical Psychiatry (N=248 adults switching between long-acting stimulants) found that 72% of patients achieved satisfactory symptom control on the first equivalent dose attempted, 19% required one dose adjustment, and 9% required two or more adjustments or a switch back to the original medication [14].

Sleep disruption is the most common complaint during the first week. If insomnia persists beyond 10 days at the starting dose, reduce the dose by one increment before concluding that the new medication is not tolerable. The FDA prescribing information for Vyvanse lists insomnia rates of 19% to 27% across pediatric and adult trials [1]; for Adderall XR, reported insomnia rates range from 12% to 17% [2]. These rates were measured during initial titration, not during mid-treatment switches, so real-world switching insomnia may differ.

Special Considerations: Binge Eating Disorder and Off-Label Uses

Vyvanse holds an FDA indication for moderate-to-severe binge eating disorder (BED) in adults, based on two key trials (N=724 combined) showing a statistically significant reduction in binge days per week (Vyvanse: 3.87-day reduction vs. placebo: 2.51-day reduction, P<0.001) [15]. Adderall XR has no BED indication. Patients who are taking Vyvanse for BED and want to switch to Adderall XR for cost or coverage reasons should understand that they would be moving to an off-label use with less clinical-trial support for that specific condition.

Both medications are sometimes prescribed off-label for treatment-resistant depression augmentation and cognitive fatigue in multiple sclerosis, but evidence for these uses remains limited to small open-label studies and case series [16]. When switching in these off-label contexts, the same dose-conversion principles apply, though the target symptoms (fatigue, cognitive processing speed) may be harder to quantify than standard ADHD rating scales.

Generic Lisdexamfetamine: Has It Changed the Switching Calculus?

Yes. The entry of generic lisdexamfetamine in August 2023 by Teva and other manufacturers reduced the average cash price from approximately $400 to $150 to $200 for a 30-day supply, based on GoodRx data from early 2024 [7]. This narrowed the cost gap with generic Adderall XR significantly, though Adderall XR generics remain less expensive at $30 to $80 per month.

Insurance formulary placement has begun shifting in response. Several large pharmacy benefit managers moved generic lisdexamfetamine to Tier 2 (preferred brand) or Tier 3, while Adderall XR generics remain Tier 1 (preferred generic) in most plans. Patients whose primary reason for switching was cost should re-check their current formulary before making a change, as the economics may have shifted since they last looked [7].

Long-Term Outcomes: Does It Matter Which One You Stay On?

The MTA follow-up studies tracked outcomes through 16 years post-randomization. By the 8-year follow-up (N=436 remaining), there were no significant differences in ADHD symptom severity, academic achievement, or functional outcomes between participants who stayed on any specific stimulant formulation versus those who switched [17]. The authors concluded that "medication type was less predictive of long-term outcome than medication consistency, dose optimization, and co-occurring conditions."

This finding aligns with a 2020 Cochrane review of amphetamine-based medications for adult ADHD (27 trials, N=4,936), which found no statistically significant differences in efficacy between lisdexamfetamine and mixed amphetamine salts when both were dosed optimally (standardized mean difference in ADHD rating scale scores: 0.04 to 95% CI: -0.08 to 0.16) [6]. The practical takeaway: the best stimulant is the one the patient takes consistently, tolerates well, and can access without interruption.

Patients who have been stable on one medication for more than 12 months without side effects or coverage issues have no clinical reason to switch. The FDA prescribing information for both drugs includes 12-month open-label extension data showing sustained efficacy without evidence of pharmacologic tolerance at stable doses [1][2].